| Quinnessential Healthcare | |
|
8100 E 22nd St N Ste 100-6 Wichita KS 67226-2301 | |
| (316) 364-4100 | |
| (316) 364-4101 |
| Full Name | Quinnessential Healthcare |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 8100 E 22nd St N Ste 100-6, Wichita, Kansas |
| Authorized Official Name and Position | Julius Seece Quinn (OWNER) |
| Authorized Official Contact | 3163644100 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Quinnessential Healthcare 8100 E 22nd St N Ste 100-6 Wichita KS 67226-2301 Ph: (316) 364-4100 | Quinnessential Healthcare 8100 E 22nd St N Ste 100-6 Wichita KS 67226-2301 Ph: (316) 364-4100 |
| NPI Number | 1083212302 |
|---|---|
| Provider Enumeration Date | 10/09/2020 |
| Last Update Date | 03/04/2024 |
| Medicare PECOS PAC ID | 9830503945 |
|---|---|
| Medicare Enrollment ID | O20210202000611 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083212302 | NPI | - | NPPES |
| 78511 | Other | KS | KS LICENSE |
| Provider Name | Julius S Quinn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073883815 PECOS PAC ID: 7810277985 Enrollment ID: I20190327000047 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
| Provider Name | Julia K Ouko |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356983282 PECOS PAC ID: 8022441740 Enrollment ID: I20191210001750 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
| Provider Name | Valentina Hain |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528602414 PECOS PAC ID: 1951730530 Enrollment ID: I20200402000890 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
| Provider Name | Ruth Elizabeth Hart |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336729888 PECOS PAC ID: 5698157402 Enrollment ID: I20220822001858 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
| Provider Name | Daniel Gichini |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457058042 PECOS PAC ID: 5991179392 Enrollment ID: I20230328001914 |
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
News Archive
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.
A new report, released today by the Manhattan Institute's Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform.
Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.
While the administration this week asked the Supreme Court to take up 26 states' challenge to the Affordable Care Act, the nation's top court on Monday will hear oral arguments on whether patients and providers can challenge states' Medicaid cuts -; a case that patient advocates believe could have major implications for the implementation of health care reform.
A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).
› Verified 2 days ago
Primary Care Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 7111 E 21st St N Ste A, Wichita, KS 67206 Phone: 316-684-2851 | |
Substance Abuse At Hunter Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2318 E Central Ave, Wichita, KS 67214 Phone: 316-262-3611 Fax: 316-262-0741 | |
Freestate Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4723 E Douglas Ave, Wichita, KS 67218 Phone: 888-505-1776 Fax: 888-505-1776 | |
Robert A Sweet Md Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3122 N Cypress Dr, Suite 100, Wichita, KS 67226 Phone: 316-260-4747 | |
World Impact, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3701 E 13th St N, #400, Wichita, KS 67208 Phone: 316-682-1880 | |
The Traveling Np Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 826 N Bracken Cir, Wichita, KS 67206 Phone: 316-990-8848 | |
Healthcore Clinic Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2707 East 21st Street North, Wichita, KS 67214 Phone: 316-691-0249 Fax: 316-691-9939 |